pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›admilparant
drug · small molecule
save

admilparant

Phase 3updated 6mo ago
by Bristol-Myers Squibb Co🔗 ChEMBL
Phase 3
community read0 votes

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.

indications

indications
Pulmonary Fibrosis

all catalysts(0)

nothing on the calendar yet

Trials studying admilparant

  • phase1A Study to Assess the Effect of Food on the Drug Levels of Admilparantcompletedn=56

News(10)

  • BMS R&D head to depart amid restructure
    Bristol Myers Squibb is combining all research and development efforts under one leader as pressure rises to replenish its pipeline.
    biospace · 4d ago
  • BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
    In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…
    biospace · 18d ago
  • Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
    Syndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was appro…
    biospace · 1mo ago
  • Bristol Myers dips on ‘confounding’ lung drug results
    Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.
    biopharma_dive · 1mo ago
  • BMS’ Phase 3 win for lung drug clouded by high-dose miss
    A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awa…
    biospace · 1mo ago
  • Bristol Myers reveals a pair of Phase 3 wins for fibrosis, RayzeBio drugs
    Bristol Myers Squibb reported two Phase 3 successes on Monday morning, including for an experimental drug that recently ran into safety issues. A trial testing the lung disease program admilparant…
    endpoints · 1mo ago
  • BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
    Bristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth.
    fiercebiotech · 1mo ago
  • BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
    BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
    biospace · 1mo ago
  • BMS reports liver injury events in lung disease program, with key readout near
    Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…
    biospace · 1mo ago
  • Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshaken
    The revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has raised concerns ahead of the study’s readout, but analysts were quick to di…
    fiercebiotech · 1mo ago
view all news mentions →
generic
admilparant
indication
Idiopathic Pulmonary Fibrosis
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?